Ami Organics | Business Upturn

Ami Organics shares surge 6% as Q4 revenue jumps 37% YoY to Rs 308.5 crore, net profit up 144% YoY

Aman Shukla — Fri, 02 May 2025 07:54:25 +0000

Ami Organics Limited saw its shares surge by 6% following the release of impressive Q4 and full-year FY25 results. As of 1:23 PM, the shares were trading 5.70% higher at Rs 1,195.00.

For the quarter ended March 31, 2025, Ami Organics reported a 37% year-on-year increase in revenue from operations, reaching ₹308.5 crore compared to ₹224.95 crore in the same quarter last year. Sequentially, revenue rose by 11.2% from ₹274.99 crore in Q3FY25.

Net profit saw an even more substantial jump, soaring 144% year-on-year to ₹62.7 crore from ₹25.67 crore in Q4FY24, and up 38% quarter-on-quarter from ₹45.45 crore in the previous quarter.

The strong Q4 showing capped off a stellar full-year performance for FY25. Ami Organics’ revenue for the fiscal year surged 46.2% to ₹1,006.88 crore, compared to ₹717.47 crore in FY24. Net profit more than tripled, coming in at ₹160.42 crore, a sharp increase from ₹48.71 crore reported the previous year.

Ami Organics opened at ₹1,150.90, reaching a high of ₹1,204.60 and a low of ₹1,124.10 in today’s trading. The stock is showing strong momentum, staying closer to its 52-week high of ₹1,322.00, far above its 52-week low of ₹504.00.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Ami Organics share price falls over 50% today? Explained

Aditya Bhagchandani — Fri, 25 Apr 2025 05:12:09 +0000

Shares of Ami Organics appeared to show a significant drop of nearly 50% in some trading platforms today, but this decline is merely technical as the smallcap pharmaceutical company’s stock traded ex-split. The company implemented a 1:2 stock split, with April 25, 2025, set as the record date according to exchange filings.

Understanding the Stock Split

The stock split means each share with a face value of Rs 10 has been divided into two shares with a face value of Rs 5 each. Consequently, the share price has been adjusted in the same ratio. Shareholders who held the stock in their demat accounts as of today’s record date will benefit from this corporate action, which was approved by shareholders on March 26, 2025.

Ami Organics opened at Rs 1,111.05 on Friday, representing a 49.5% decrease from Thursday’s closing price of Rs 2,200.90. This apparent decline is entirely attributable to the subdivision of equity shares rather than any fundamental issue with the company.

Market Performance Post-Split

Following the split, the stock demonstrated strong market confidence by climbing nearly 17% to Rs 1,119 during the trading session. Later, it stabilized around Rs 1,105, ending relatively flat compared to its opening price. The company’s market capitalization remains robust at approximately Rs 9,050 crore.

Some trading applications may still display the 50% drop due to technical adjustments still being processed amid today’s market volatility.

Corporate Developments

In addition to the stock split, Ami Organics recently announced plans to change its name to ‘Acutaas Chemicals Limited.’ An extraordinary general meeting (EGM) has been scheduled for May 10, 2025, to obtain shareholder approval for this rebranding initiative.

The company’s board of directors will meet on May 2, 2025, to review and approve audited financial statements for the fourth quarter and fiscal year ending March 31, 2025. They will also consider a dividend declaration for shareholders.

Trading Restrictions and Analyst Outlook

Currently, the stock operates under the ‘T+1’ settlement cycle, imposing 5% circuit filters for the next 10 trading sessions and prohibiting intraday trading.

JM Financial projects promising results for Ami Organics’ March 2025 quarter, with anticipated revenue of Rs 285 crore (up 26.7% year-over-year and 3.6% quarter-over-quarter). The brokerage maintains a ‘buy’ rating with a pre-split target price of Rs 2,605, forecasting strong EBITDA and net profit growth.

Investors should understand that the apparent 50% price drop reflects only the technical adjustment from the stock split rather than any deterioration in the company’s financial health or market position

Ami Organics commissions 10.8 MW solar plant, advancing sustainability goals

Aman Shukla — Thu, 03 Apr 2025 10:23:39 +0000

Ami Organics Limited (AMI), a global leader in pharmaceutical intermediates and specialty chemicals, has successfully commissioned its 10.8 MW DC solar power plant in Pratapnagar, Narmada District, Gujarat. This marks a significant step toward the company’s commitment to sustainability and energy efficiency.

The newly operational solar plant consists of two captive units of 5.4 MW each and will power Ami Organics’ Ankleshwar and Jhagadia units, leading to substantial cost savings. This initiative is part of the company’s broader goal of establishing a total solar capacity of 15.80 MW, as approved by its Board of Directors.

In addition to the 10.8 MW plant, the company is developing another 5 MW solar facility, expected to be completed soon. This plant will cater to the electricity needs of its Sachin unit in Surat, ensuring that a significant portion of its energy demand is met through renewable sources.

By transitioning to solar energy, Ami Organics reinforces its commitment to reducing its carbon footprint and operational expenses while aligning with India’s net-zero targets. This strategic move not only strengthens the company’s sustainability roadmap but also enhances its long-term business growth and environmental responsibility.

Ami Organics stock surges 27% this week on strong Q2 FY25 results

Aman Shukla — Sat, 02 Nov 2024 09:13:53 +0000

Ami Organics shares have soared over 27% this week, driven by a stellar Q2 FY25 earnings report. The company showcased impressive financial growth, with revenue jumping by 43% quarter-on-quarter (QoQ) and 44% year-on-year (YoY), reaching ₹246.73 crore.

The company’s net profit also saw a remarkable turnaround, hitting ₹37 crore in Q2, a 154% QoQ increase, especially significant compared to the net loss of ₹24 crore in the same quarter last year.

On Friday, Ami Organics stock opened at ₹1,901, reached a high of ₹1,994, and a low of ₹1,870.60, showcasing increased investor interest and confidence in the company’s future growth.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Ami Organics shares surge over 28% in three days

Aditya Bhagchandani — Wed, 30 Oct 2024 05:15:37 +0000

Ami Organics has reported a robust Q2 performance, with revenue rising by 43% QoQ and 44% YoY to ₹246.73 crore, showcasing solid growth.

The company also turned a net profit of ₹37 crore, marking a 154% QoQ improvement compared to a net loss of ₹24 crore in the same quarter last year.

Following these impressive results, Ami Organics raised its FY25 revenue growth guidance from 25% to 30%, bolstering its position in the specialty chemicals sector and fueling positive investor sentiment.

As of 10:44 am the shares were trading 7.55% higher at ₹1,957.85 –

Ami Organics Share Price history

Day	Open	Close	Change %
Tue, Oct 29 2024	₹1,623.10	₹1,820.35	+12.95%
Mon, Oct 28 2024	₹1,507.95	₹1,611.65	+6.82%
Fri, Oct 25 2024	₹1,523.80	₹1,508.75	-2.18%
Thu, Oct 24 2024	₹1,530.35	₹1,542.30	+0.01%
Wed, Oct 23 2024	₹1,470.00	₹1,542.20	+4.48%
Tue, Oct 22 2024	₹1,580.00	₹1,476.10	-6.30%
Mon, Oct 21 2024	₹1,595.00	₹1,575.40	-0.96%
Fri, Oct 18 2024	₹1,605.00	₹1,590.60	-0.31%

Ami Organics shares jump over 4% on strong Q2 FY25 performance, revenue growth guidance raised

Aditya Bhagchandani — Wed, 30 Oct 2024 04:53:38 +0000

Ami Organics shares surged 4.65% to ₹1,905.00 on the NSE as of 10:22 am, following an impressive Q2 FY25 earnings report that showcased robust growth across key financial metrics.

Q2 Financial Highlights

Revenue: Increased by 43% QoQ and 44% YoY to ₹246.73 crore, indicating substantial expansion.
Net Profit: Achieved a significant turnaround with a net profit of ₹37 crore, a 154% increase QoQ, compared to a net loss of ₹24 crore in the same quarter last year.

Following this strong performance, Ami Organics has revised its FY25 revenue growth guidance from 25% to 30%, reflecting confidence in its strategic initiatives and market expansion. The company’s results highlight its position as an emerging leader in the specialty chemicals sector, driving positive investor sentiment and lifting the stock price today.

Why Ami Organics shares are 14% up today? Check out the reason

Aditya Bhagchandani — Tue, 29 Oct 2024 08:17:46 +0000

Ami Organics shares surged by 14% following the release of impressive Q2 FY25 financial results, showcasing substantial growth in revenue and profitability. As of 1:44 pm, the shares were trading 13.86% higher at ₹1,835.00 on the NSE.

Key Financial Highlights for Q2 FY25:

Revenue Growth: Ami Organics reported a robust 43% increase in revenue quarter-over-quarter (QoQ) and a 44% rise year-over-year (YoY), reflecting strong demand and sales performance.
Net Profit: The company achieved a net profit of ₹37 crore, marking a significant turnaround from a net loss of ₹24 crore in the same quarter last year. This represents a remarkable 154% QoQ growth in net profit, highlighting effective cost management and operational efficiency.

Additionally, Ami Organics has revised its revenue growth guidance for FY25, raising it from 25% to 30% in light of the strong Q2 results. This upward revision underscores the company’s expanding market footprint and solidifies its position as a key player in the specialty chemicals sector.

Ami Organics Q2 Results: Revenue grows 44% YoY, Net profit jumps to ₹37 crore

Aditya Bhagchandani — Tue, 29 Oct 2024 06:54:01 +0000

Ami Organics has posted impressive financial results for the second quarter of FY25, showcasing robust growth in revenue and profitability. This performance underscores the company’s successful efforts to drive growth and expand its market reach.

Q2 Financial Highlights:

Revenue: The company’s revenue surged by 43% quarter-on-quarter (QoQ) and by 44% year-on-year (YoY), reaching ₹246.73 crore for the quarter ended September 30, 2024.
Net Profit: Ami Organics recorded a remarkable turnaround in net profit. The net profit stood at ₹37 crore, representing a 154% increase QoQ. Comparatively, the company had reported a net loss of ₹24 crore in the same quarter last year, reflecting significant improvement YoY.

These results underscore Ami Organics’ strong operational and strategic performance, marking a positive trajectory in its financial health and growth potential in the specialty chemicals sector.

AMI Organics share price surges over 4% after JM Financial initiates Buy, expects stock to rally 20%

Aditya Bhagchandani — Mon, 23 Sep 2024 04:45:53 +0000

Shares of AMI Organics surged more than 4% on Monday morning after JM Financial initiated a ‘Buy’ rating on the stock, forecasting a 20% upside. The brokerage firm set a target price of ₹1,965, expecting significant growth driven by new contract wins and a strong product pipeline. The stock, which closed at ₹1,629.60 on Friday, saw a strong response from investors, reflecting growing confidence in the company’s growth prospects.

Key Growth Drivers

JM Financial’s optimistic outlook for AMI Organics is based on the company’s expansion into new high-growth sectors and its ability to scale existing operations. The brokerage highlighted two key catalysts for growth:

Nubeqa Intermediates Contract
AMI Organics is supplying five intermediates for the production of Nubeqa, a prostate cancer drug developed by Bayer and Fermion. The contract is expected to account for around 60% of AMI’s incremental revenue growth. The market size for Nubeqa intermediates could reach up to ₹12 billion by 2030, with AMI projected to capture 50-60% of the market, translating to ₹5-7 billion in revenue. This contract alone is poised to be a game changer for AMI’s revenue growth.
Electrolyte Additives for Li-ion Batteries
AMI Organics is also set to benefit from its venture into the production of electrolyte additives for lithium-ion batteries, such as Vinylene Carbonate (VC) and Fluorothylene Carbonate (FEC). These additives are crucial for battery efficiency and are in high demand. AMI is the first manufacturer of these additives outside China, giving it a competitive edge. The company has already signed long-term contracts for these products, with revenue expected to reach ₹400 million in FY25, ₹1 billion in FY26, and ₹1.5 billion by FY27. Additionally, AMI has signed an MoU with a global electrolyte manufacturer to further increase its presence in the battery industry by FY28.

Strong Advanced Intermediates Business

AMI Organics has built a solid foundation through its pharma intermediates business, which contributes significantly to its revenue. The company supplies intermediates for various APIs (Active Pharmaceutical Ingredients) used in fast-growing chronic therapies. With a market share of 50-90% in these intermediates, AMI continues to strengthen its position through 10+ years of patent protection for its key products.

The company also stands to benefit from recent legal wins for pharmaceutical giants like Teva and Sandoz, which will soon launch generic versions of drugs like Apixaban and Rivaroxaban. AMI’s intermediates are used in these drugs, and the expansion of generics markets will drive demand for the company’s products.

Expected Financial Performance

JM Financial expects AMI Organics to post impressive revenue and profit growth over the next few years. The brokerage forecasts a 31% revenue CAGR (Compound Annual Growth Rate) from FY24 to FY27, driven by new contracts, including Nubeqa intermediates and electrolyte additive sales. EBITDA is expected to grow at a 44% CAGR, while EPS could surge by 76% during the same period.

AMI’s gross margins are projected to improve as its Contract Development and Manufacturing Organization (CDMO) business grows, along with savings from its captive solar power generation project. EBITDA margins are expected to rise from 18% in FY24 to around 24% in FY27.

Strategic Moves and Future Outlook

In addition to its expanding presence in the pharma and battery segments, AMI Organics is entering the semiconductor chemical market through its acquisition of a controlling stake in Baba Fine Chemicals. This move allows AMI to tap into a high-entry-barrier industry and diversify its revenue streams further.

JM Financial’s positive assessment of AMI Organics highlights the company’s strong R&D capabilities, operational excellence, and strategic focus on high-growth sectors. The firm expects these factors to drive long-term growth and position AMI as a leader in the specialty chemicals industry.

Share Performance

As of 10:12 AM on Monday, shares of AMI Organics were trading 3.54% higher at ₹1,689.05 on the NSE, driven by JM Financial’s bullish outlook and increased investor interest

AMI Organics’ Sachin Facility receives GMP compliance from PMDA Japan

Aditya Bhagchandani — Sat, 07 Sep 2024 15:04:20 +0000

AMI Organics has announced that the Pharmaceutical and Medical Devices Agency (PMDA) Japan has declared its Sachin manufacturing facility in Surat as compliant with Good Manufacturing Practices (GMP). This announcement follows an earlier update from the company on June 7, 2024, regarding the completion of the GMP inspection at the Sachin facility.

The inspection was conducted to ensure that the facility meets the required manufacturing standards, and the positive result reaffirms the company’s commitment to maintaining high-quality production practices. This certification is expected to enhance AMI Organics’ reputation and expand its footprint in global markets.

Ami Organics Stock: Share price jumps 7.5% this week after HDFC Securities upgrades stock to Buy

Aman Shukla — Sat, 31 Aug 2024 08:54:57 +0000

Ami Organics Limited, a major speciality chemical manufacturer, witnessed a 7.55% rise in stock price this week on the National Stock Exchange (NSE).

The main cause of this growth is the upgrade by HDFC Securities, a renowned brokerage company. HDFC Securities has raised Ami Organics to a ‘Buy’ rating and set a target price of ₹1,600 per share.

Ami Organics’ margins are expected to rise 508 basis points from 17.9% in FY24 to 23% in FY26, according to HDFC Securities. The brokerage also anticipates the company’s earnings to expand at a 38% compound annual growth rate (CAGR) during FY24-26, owing to a 29% CAGR in EBITDA.

Stock Performance on Friday

– Open: ₹1,365.00

– High: ₹1,398.00

– Low: ₹1,363.00

AMI Organics share price surges 3.5% as HDFC Securities upgrades stock to Buy

News Desk — Wed, 28 Aug 2024 04:07:51 +0000

Ami Organics Limited, a leading manufacturer of specialty chemicals, saw its stock price surge by 3.4% on the National Stock Exchange (NSE) today. The stock closed at ₹1,332.75, up ₹43.85 from its previous close of ₹1,288.90.The stock opened at ₹1,290.00 and touched an intraday high of ₹1,339.95 before closing at ₹1,332.75. The trading volume was higher than usual, indicating increased investor interest in the stock.The primary reason behind this growth is the upgrade by HDFC Securities, a leading brokerage firm. HDFC Securities has upgraded Ami Organics to a ‘Buy’ rating with a target price of ₹1,600 per share. The upgrade is based on the following factors:

Ramp-up in Fermion contract: Ami Organics has secured a significant contract with Fermion, a leading pharmaceutical company, which is expected to contribute to the company’s revenue growth.
Expansion of specialty chemicals portfolio: The company has been actively expanding its portfolio of specialty chemicals, which are expected to generate higher margins.
Balance sheet turning net cash in Q1FY25: Ami Organics’ balance sheet is expected to turn net cash positive in the first quarter of fiscal year 2025, indicating strong financial health.
Increase in better-margin CDMO contribution: The company’s Contract Development and Manufacturing Organization (CDMO) business is expected to contribute a larger share of revenue, which will result in higher margins.
Ramp-up in capacity utilization of specialty chemicals plant: Ami Organics’ specialty chemicals plant is expected to operate at higher capacity utilization levels, leading to improved profitability.

HDFC Securities expects Ami Organics’ margins to improve by 508 basis points from 17.9% in FY24 to 23% in FY26. The brokerage also expects the company’s profit to grow at a 38% compound annual growth rate (CAGR) over FY24-26, driven by a 29% CAGR in EBITDA.Investors are advised to closely monitor the company’s performance and consult with financial advisors before making any investment decisions.

Note: All data as on 9:34, 28 Aug 2024

Disclaimer: This article is for informational purposes only and reflects the views of HDFC Securities. The opinions expressed herein do not necessarily represent the views of the author or the publication. Readers are encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. The author and publication assume no responsibility for any losses or damages arising from reliance on the information provided in this article.

Ami Organics shares surge 9% after board approves QIP

Aditya Bhagchandani — Wed, 19 Jun 2024 06:14:34 +0000

Ami Organics saw its shares jump nearly 9% after its board approved the opening of a qualified institutional placement (QIP) of equity shares. The floor price has been set at ₹1,228.71 per share.

The company’s board authorized and declared the opening of the issue on Tuesday, June 18, 2024. The floor price is at a 6.23% discount to the previous day’s closing price of ₹1,310.30 on the BSE. The company may offer a discount of up to 5% on the floor price for the issue.

A committee meeting is scheduled for Friday, January 21, 2024, to consider and approve the issue price of the equity shares.

Ami Organics, engaged in the business of drug intermediate chemicals and related activities, reported a 4.2% decline in consolidated net profit to ₹260 crore, despite a 20.7% increase in revenue from operations to ₹2,250 crore in Q4 FY24 over Q4 FY23.

As of 11:12 AM, the shares were trading 8.45% higher at ₹1,421.75 on the NSE.

Ami Organics to raise Rs 500 crore via QIP

Markets Desk — Fri, 12 Apr 2024 13:18:04 +0000

The board of Ami Organics on Friday, April 12 approved the fund raising plan for the company via the route of Qualified Institutions Placement (QIP), the company said in an exchange filing on Friday evening. The company’s board has approved fund raising of Rs 500 crore via the QIP route, details of which are still not disclosed.

“Board approved the proposal for raising of funds in one or more tranches by way of issuance of such number of equity shares having face value ₹ 10 each of the Company (“Equity Shares”) and/or other securities convertible into Equity Shares, fully convertible debentures, with or without warrants and/or preference shares or any security convertible into Equity Shares or any combination thereof (hereinafter referred to as “Securities”), for an aggregate amount not exceeding ₹ 5,000 million (Rupees five thousand million only) by way of qualified institutions placement (“QIP”),” the company said.

Shares of Ami Organics ended 4.2% lower at Rs 1,220.95 on the BSE on Friday.

Stocks To Watch Today: IGL, Avenue Supermarts, AMI Organics, DLF, Adani Enterprises

Markets Desk — Mon, 15 May 2023 01:36:11 +0000

The SGX Nifty signals a weak start for the Sensex, Nifty today. Cues from US markets remained mixed as Dow Jones, S&P 500 and Nasdaq ended in red on Friday. Markets in India recovered sharply on Friday, with the Nifty comfortably ending above the 18,300 mark.

Top stocks to watch today are IGL, Avenue Supermarts, AMI Organics, DLF, Adani Enterprises, besides others.

IGL: Shares of Indraprastha Gas Ltd (IGL) will be in focus today on the back of its Q4 numbers. The company reported a operational miss in the quarter, with margins coming in lower than the analyst and street expectations. The company’s revenue came in at Rs 3,685 crore against Rs 3,711 crore in the previous quarter. Margin came in at 12.6% against a CNBC-TV18 poll of 13.8%.

Avenue Supermarts (DMart): Avenue Supermarts reported a good set of Q4 numbers with its net profit coming in higher by 8% on a YoY basis at Rs 460 crore against Rs 426 crore in Q4FY22. The company’s revenue grew 20.6% to Rs 10,594 crore against Rs 8,786 crore in the same quarter last year.

Adani Enterprises: Shares of Adani Enterprises will be in focus today as the company’s board has approved a fund raise of Rs 12,500 crore via QIP.

Ami Organics, DLF, Max Financials will be a few other stocks in focus on the back of their Q4 numbers.

Ami Organics to invest Rs 190 crore to expand brownfield capacity

United News of India (UNI) — Fri, 29 Apr 2022 08:10:43 +0000

Speciality Chemicals manufacturer Ami Organics on Friday said it will invest Rs 190 crore for the development of the brownfield facility in Ankleshwar acquired from Gujarat Organics last year. “The board of directors of the company has approved the capex plan of Rs 190 crore to build a brownfield plant in Ankleshwar, Gujarat, to support the future business growth in the company’s advanced pharmaceutical intermediates segment,” it said in a regulatory filing.

Ami Organics acquired two facilities at Ankleshwar and Jhagadia from the Gujarat Organics on March 31, 2021. “The capex will be funded through a mix of general corporate funds of IPO proceeds, internal accruals, and debt. Currently, the company does not have long-term debt on the books other than a short-term working capital loan,” it said. The company noted that the production at the Ankleshwar unit was successfully transferred to the Jhagadia unit during the last quarter for optimum utilisation of resources without losing any revenue.

Currently, the old plant at Ankleshwar is being demolished and the new plant will be built on this site, it said adding that it has received necessary environmental clearance for the same. “The new facility will have 90 reactors taking the total reactor capacity to 436KL. The plant is expected to start commercial operations from Q4FY24,” it added. The current capacity utilisation at the Sachin unit in Surat, Gujarat. Which manufactures the majority of the pharmaceutical intermediates is at 65 per cent. Commenting on the capex plan, Nareshkumar Patel, Executive Chairman and Managing Director, Ami Organics said. “We envisage an increase in demand for our existing products as well as for our products in the pipeline. The capex-that we have planned will help us cater to this growing demand till 2027-28”. He further said to ensure.

That the company has enough capacity to cater to the growing demand. Until the new project at Ankleshwar is complete. It is in the process of shifting some of its existing. As well as new products to continuous flow reactors. This will help free up a considerable capacity at the Sachin unit. “We will continue to invest in improving our processes and strategically shift high volume products to advanced technology that will allow our business to stay sustainable and maintain our margins given the uncertain external global environment and supply-chain challenges,” Patel added.

(Except for the headline. This story has not been edited by Business Upturn staff. And is published from a syndicated feed.)

Ami Organics IPO share allocation to be finalized on September 8, Details here

Sneha Sengupta — Wed, 01 Sep 2021 08:35:50 +0000

On September 3, Ami Organics’ initial public offering commenced today wherein the issue closes on September 3. However, before launching its IPO, the chemical manufacturer has already accumulated ₹171 crore from its anchor investors. It delegated around 28,01,485 equity shares to its 20 anchor investors with an upper bank Rs 610 apiece, comprising SBI Healthcare Fund, SBI Mutual Fund, Kuber India Fund and UTI Healthcare Fund, respectively. At 11:35 am, Ami Organics IPO was subscribed by 0.58 times. This company has ascertained a price range of 603-610/share for the ₹570 crore IPO.

Lot size and allotment details

Ami Organics lot size is 24 equity shares and can be displayed for bidding in multiples of 24 pertaining to the equity shares. The division goes this way: 35% has been set aside for retail investors, 50% reserved for qualified institutional investors and the leftover 15 per cent for non-institutional investors. The allocation date is most probable to be announced by September 8 and the tentative listing date arrives to be on September 4. Link Intime India Private Ltd is the IPO registrar for the company.

A freshly mapped GMP

The grey market observers claim that Ami Organics shares are indicating a premium of ₹162 wherein its IPO includes a new issue of Rs. 200 crores with an offer of sales of 6,059,600 equity shares by shareholders. After the IPO bidding, the promoter’s holdings may decline from 47.2% to 41.1%.

Financials of Ami Organics

Ami Organics gathers a maximum percentage of its revenue from global market investors. Exports conferred 51.5% of the company’s revenues with effect from March 2021. As of FY21, the company has accounted for revenues worth ₹340 crore with a net profit of ₹54 crore.

Comments

“The company has shown consistent financial performance with sales growth at CAGR of 19.5% and restated profit after tax growth at CAGR of 52.3% between the Fiscals 2019 and 2021. The financials for 2020-21 doesn’t include revenue from the acquisition of the two plants. We are positive about the long-term prospects of the Company. Hence, we recommend a “Subscribe” rating to this IPO,” suggests brokerage, Anand Rathi.

Ami Organics issue is available at the upper end of the IPO price band at 41.2x its FY21 earnings, with a market cap of Rs. 22,227 million. Further on the FY21 earnings basis, the company is trading below the industry average of 48.91x. Looking at the P/B ratio on the upper price band, book value and P/B are Rs. 53 and 11.51x respectively along with a RoNW of 32.35%, Anand Rathi averred.

Ami Organic IPO to open for bidding on September 1: Details here

Sneha Sengupta — Mon, 30 Aug 2021 05:54:32 +0000

The chemical manufacturing company with an overall public issue of ₹569.64 crore is all set to step into Dalal Street on 1st September 2021. The public issue will commence its bidding with effect from September 1 till September 3, the last for its subscription. According to the company’s promoters, Ami Organics IPO price band will range from ₹603 to ₹610. The company’s shares is can be availed today at a premium rate of ₹50 in the grey market.

Following are some specifications of Ami Organics IPO:

Ami Organics IPO GMP Ratings

At ₹50 the premium of the company’s share was decided to be dispatched in the grey market today. Therefore the grey market may certainly get a ₹50 listing gain from this public issue compared to the issue price of ₹603-₹610. Meanwhile, today Ami Organics IPO GMP dipped against its yesterday price of ₹68. However, market observers said the pricing was deterred due to the effect of non-trading days but are now expecting and estimating an increase on Monday and Tuesday.

Other details:

– Ami Organics IPO price: As decided by the promoters, it will range from ₹603 to ₹610.

– Ami Organics IPO size: With a ₹569.64 crore public issue including ₹200 crore, it will also comprise an Offer for Sale (OFS) of ₹369.64 crore.

– Ami Organics IPO allotment date: The allotment of shares will commence from 8th September 2021.

IPO order size: A lot can comprise at least 24 shares of the company. A bidder can avail of a minimum of one lot and a maximum of 13 lots.

Investment dimension: A bidder can bid for atleast one lot and maximum upto 13 lots with an investment of at least ₹14,640 ( ₹610 x 24) and maximum ₹1,90,320 ( ₹610 x 24 x 13).

Listing date: Company’s shares will be listed at both NSE and BSE. However, the listing date for the Indian market is tentative on 14th September 2021.